{
    "id": 2968,
    "fullName": "AR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AR positive indicates the presence of the AR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "positive",
    "createDate": "01/29/2015",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with ABC294640 resulted in decreased AR and MYC expression and downstream signaling, and decreased growth of AR-positive prostate cancer cell lines in culture, and inhibited tumor growth in prostate cancer cell line xenograft models (PMID: 26271487).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3301,
                "therapyName": "ABC294640",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4127,
                    "pubMedId": 26271487,
                    "title": "Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26271487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11068,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CCS1477 resulted in decreased expression of full length AR, AR-V7, and c-MYC, and inhibited proliferation of prostate cancer cells in culture and inhibited tumor growth in xenograft models (J Clin Oncol 35, 2017 (suppl; abstr 11590)).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 5852,
                "therapyName": "CCS1477",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9061,
                    "pubMedId": null,
                    "title": "Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_189631.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5887,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 and Xtandi (enzalutamide) worked synergistically to inhibit growth in AR-positive prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3971,
                "therapyName": "Enzalutamide + G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12339,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UT-155 decreased AR expression and transcriptional activity and inhibited proliferation prostate cancer cell lines expressing full length AR and/or AR splice variants, and inhibited tumor growth in xenograft models (PMID: 28978635).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6460,
                "therapyName": "UT-155",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10333,
                    "pubMedId": 28978635,
                    "title": "Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17000,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Androgen receptor therapy, such as Lupron (leuprolide) is included in guidelines for patients with AR-positive salivary gland tumors (NCCN.org).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 795,
                "therapyName": "Leuprolide",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11539,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tanespimycin (17-AAG) and Xtandi (enzalutamide) resulted in decreased AR expression and signaling, increased cell death, and decreased growth of prostate cancer cell lines in culture, and decreased tumor growth in patient-derived xenograft (PDX) models compared to either agent alone (PMID: 27390342).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6022,
                "therapyName": "Enzalutamide + Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9608,
                    "pubMedId": 27390342,
                    "title": "Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27390342"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16493,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tertomotide (GV1001) inhibited growth of AR-positive prostate cancer cells in culture and induced apoptosis in cell line xenograft models (PMID: 30400054).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 8067,
                "therapyName": "Tertomotide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14562,
                    "pubMedId": 30400054,
                    "title": "Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30400054"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2468,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Xtandi (enzalutamide) resulted in a mean progression-free survival of 14 weeks and clinical benefit in 29% (22/75) of patients with AR-positive triple negative breast cancer, with improved response demonstrated in patients with AR-driven gene expression (J Clin Oncol 33, 2015 (suppl; abstr 1003).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3124,
                    "pubMedId": null,
                    "title": "Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).",
                    "url": "http://meetinglibrary.asco.org/content/150040-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10002,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, high-dose Dutasteride following Zytiga (abiraterone) treatment resulted in more than 50% reduction of prostate-specific antigen level in 60% (24/40) of patients with metastatic castration-resistant prostate cancer, 94% (29/31) of tested tumor were positive for nuclear Ar (PMID: 27683182).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 5340,
                "therapyName": "Abiraterone + Dutasteride",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7893,
                    "pubMedId": 27683182,
                    "title": "A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27683182"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12206,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-485 treatment in AR positive castration-resistant prostate cancer cells inhibited proliferation in culture, and induced tumor growth inhibition by 54% in cell line xenograft models (PMID: 28953875).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6354,
                "therapyName": "A-485",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10155,
                    "pubMedId": 28953875,
                    "title": "Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28953875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12229,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GNE-049 reduced AR target gene expression and growth of AR-expressing prostate cancer cell lines in culture, and inhibited tumor growth in AR-expressing patient-derived xenograft (PDX) models of prostate cancer, including castration-resistant prostate cancer models (PMID: 28819026).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6371,
                "therapyName": "GNE-049",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10185,
                    "pubMedId": 28819026,
                    "title": "Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5894,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ODM-207 inhibited proliferation of AR-positive prostate cancer cell lines in culture and suppressed tumor growth in patient-derived xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #4649).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3974,
                "therapyName": "ODM-207",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5186,
                    "pubMedId": null,
                    "title": "ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=177af784-a1f1-406c-9aa8-67b47302d29b&cKey=a3591182-1c63-4601-8452-da8fc4cf389d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16999,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Androgen receptor therapy, such as Casodex (bicalutamide), is included in guidelines for AR-positive salivary gland tumors (NCCN.org).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20290,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KCI807 treatment inhibited growth of AR-positive prostate cancer cell lines in culture, and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 30185422).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 9310,
                "therapyName": "KCI807",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17793,
                    "pubMedId": 30185422,
                    "title": "Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5087,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and Xtandi (enzalutamide) resulted in tumor growth inhibition in xenograft models of an AR-dependent, PTEN-mutant human prostate cancer cell line (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3751,
                "therapyName": "Alpelisib + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5086,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XTANDI (enzalutamide) treatment resulted in tumor growth inhibition in cell line xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in complete inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3752,
                "therapyName": "AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5083,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3749,
                "therapyName": "Alpelisib + AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5080,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) treatment resulted in minor inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5081,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 treatment resulted in minor inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5084,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186, Alpelisib (BYL719) and Xtandi (enzalutamide) combination treatment resulted in tumor regression in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3750,
                "therapyName": "Alpelisib + AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14949,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and RAD140 resulted in enhanced antitumor efficacy in AR/ESR1-positive breast cancer patient-derived xenograft (PDX) models compared to either agent alone (PMID: 28974548).",
            "molecularProfile": {
                "id": 26899,
                "profileName": "AR pos ESR1 pos"
            },
            "therapy": {
                "id": 7216,
                "therapyName": "Palbociclib + RAD140",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11832,
                    "pubMedId": 28974548,
                    "title": "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28974548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14948,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with RAD140 inhibited proliferation of AR/ESR1-positive breast cancer cells in culture and blocked tumor growth in AR/ESR1-positive breast cancer patient-derived xenograft (PDX) models (PMID: 28974548).",
            "molecularProfile": {
                "id": 26899,
                "profileName": "AR pos ESR1 pos"
            },
            "therapy": {
                "id": 7211,
                "therapyName": "RAD140",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11832,
                    "pubMedId": 28974548,
                    "title": "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28974548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9632,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with salivary duct carcinoma positive for ERBB2 and AR demonstrated sensitivity to the combination of Herceptin (trastuzumab), Paraplatin (carboplatin), and Taxotere (docetaxel), resulting in a partial response after 2 cycles of treatment (PMID: 27334835).",
            "molecularProfile": {
                "id": 26939,
                "profileName": "AR pos ERBB2 pos"
            },
            "therapy": {
                "id": 1485,
                "therapyName": "Carboplatin + Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 50904,
                "name": "salivary gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7355,
                    "pubMedId": 27334835,
                    "title": "Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27334835"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9634,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two patient with salivary duct carcinoma positive for AR and harboring NCOA4-RET demonstrated clinical efficacy when treated with Cometriq (Cabometyx, cabozantinib (PMID: 27334835).",
            "molecularProfile": {
                "id": 26940,
                "profileName": "NCOA4 - RET AR pos"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 50904,
                "name": "salivary gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7355,
                    "pubMedId": 27334835,
                    "title": "Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27334835"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 and Xtandi (enzalutamide) combination treatment resulted in greater tumor growth inhibition compared to MI-503 treatment alone in cell line xenograft models of AR-, KMT2A- and MEN1-positive prostate cancer (PMID: 25822367).",
            "molecularProfile": {
                "id": 35165,
                "profileName": "AR pos KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 9344,
                "therapyName": "Enzalutamide + MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17831,
                    "pubMedId": 25822367,
                    "title": "Targeting the MLL complex in castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25822367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KCI807 treatment inhibited colony formation and growth of prostate cancer cell lines expressing AR V7_splice and AR in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 30185422).",
            "molecularProfile": {
                "id": 35181,
                "profileName": "AR V7_splice AR pos"
            },
            "therapy": {
                "id": 9310,
                "therapyName": "KCI807",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17793,
                    "pubMedId": 30185422,
                    "title": "Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xtandi (enzalutamide) treatment resulted in greater inhibition of AR signaling, androgen biosynthesis genes expression, and proliferation in prostate cancer cells harboring TMPRSS2-ERG compared to ERG knockdown cells in culture, and significantly reduced tumor burden in an intratibial xenograft model (PMID: 31638934).",
            "molecularProfile": {
                "id": 35331,
                "profileName": "TMPRSS2 - ERG AR pos"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18033,
                    "pubMedId": 31638934,
                    "title": "TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31638934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2795,
            "profileName": "AR positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20265,
            "profileName": "AR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26899,
            "profileName": "AR pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26908,
            "profileName": "AR pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26909,
            "profileName": "AR pos ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26939,
            "profileName": "AR pos ERBB2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26940,
            "profileName": "NCOA4 - RET AR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31574,
            "profileName": "AR pos BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35165,
            "profileName": "AR pos KMT2A pos MEN1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35181,
            "profileName": "AR V7_splice AR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35331,
            "profileName": "TMPRSS2 - ERG AR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}